Jiwei Zhang

Mr. Jiwei Zhang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Science Advances
Verified
Journal Article
Open access
Feixiang BaoFeixiang Bao
Feixiang Bao
LZLingyan Zhou
Lingyan Zhou
RZRui Zhou
Rui Zhou
QHQiaoying Huang
Qiaoying Huang
JCJunguo Chen
Junguo Chen
Xingguo LiuXingguo Liu
Xingguo Liu
Mitochondrial quality control plays an important role in maintaining mitochondrial homeostasis and function. Disruption of mitochondrial quality control degrades brain function. We found that flunarizine (FNZ), a drug whose chronic use causes parkinsonism, led to a parkinsonism-like motor dysfunction in mice. FNZ induced mitochondrial dysfunction and decreased mitochondrial mass specifically in the brain. FNZ decreased mitochondrial content in both neurons and astrocytes, without affecting the number of nigral dopaminergic neurons. In human neural progenitor cells, FNZ also induced mitochondrial depletion. Mechanistically, independent of ATG5- or RAB9-mediated mitophagy, mitochondria were engulfed by lysosomes, followed by a vesicle-associated membrane protein 2– and syntaxin-4–dependent extracellular secretion. A genome-wide CRISPR knockout screen identified genes required for FNZ-induced mitochondrial elimination. These results reveal not only a previously unidentified lysosome-associated exocytosis process of mitochondrial quality control that may participate in the FNZ-induced parkinsonism but also a drug-based method for generating mitochondria-depleted mammal cells.

13 February 2017 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
CWChao Wu
Chao Wu
DCDing‐Bang Chen
Ding‐Bang Chen
LFLi Feng
Li Feng
XZXiang‐Xue Zhou
Xiang‐Xue Zhou
JZJiwei Zhang
Jiwei Zhang
XLXun‐Hua Li
Xun‐Hua Li

1 February 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JZJiwei Zhang
Jiwei Zhang
JLJun-Xiu Liu
Jun-Xiu Liu
HHHai-Man Hou
Hai-Man Hou
DCDing-Bang Chen
Ding-Bang Chen
LFLi Feng
Li Feng
XLXun-Hua Li
Xun-Hua Li

13 December 2013 in Journal of Computational Neuroscience
Verified
Journal Article
Closed access
PDF file
JZJiwei Zhang
Jiwei Zhang
DZDouglas Zhou
Douglas Zhou
DCDavid Cai
David Cai
ARAaditya V. Rangan
Aaditya V. Rangan

1 August 2015 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
LZLi-Na Zhou
Li-Na Zhou
JZJiwei Zhang
Jiwei Zhang
XLXiao-Lin Liu
Xiao-Lin Liu
LZLihua Zhou
Lihua Zhou

22 May 2016 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
DCDingbang Chen
Dingbang Chen
XZXiangxue Zhou
Xiangxue Zhou
HHHaiman Hou
Haiman Hou
LFLi Feng
Li Feng
JLJunXiu Liu
JunXiu Liu
XLXunhua Li
Xunhua Li
There are limited pharmacological treatments for patients with neurological Wilson’s disease (WD) and a history of copper-chelating treatment failure. We retrospectively evaluated the clinical records of 38 patients with WD who were treated with sodium dimercaptopropanesulfonate (DMPS) and zinc (group 1) or zinc alone (group 2). All patients had a history of neurological deterioration during their previous treatment with D-penicillamine (DPA). Twenty-one patients were treated with intravenous DMPS for 4 weeks, followed by zinc gluconate for 6 months, and the treatment protocol was repeated twice. Relative to the baseline, repeated DMPS therapy and zinc maintenance therapy decreased neurological scores continuously (p < 0.01). Sixteen patients (76.2%) demonstrated neurological improvements after 1 year of therapy and four patients (19.0%) exhibited neurological deterioration at the follow-up session. In addition, 17 patients were treated with zinc monotherapy for 12 months. Two patients (11.8%) demonstrated neurological improvements and five patients (29.4%) exhibited neurological deterioration. Compared with the patients in group 2, a greater improvement ratio (p < 0.01) and lower deterioration ratio (p < 0.01) were observed in the patients in group 1 after 1 year of therapy. Our findings indicate that the safety and efficacy of combined treatment of DMPS and zinc is superior to those of zinc monotherapy in patients with neurological WD with a history of DPA treatment failure.